中断伴化脓性关节炎、坏疽性脓皮病和痤疮综合征中IFN-γ依赖的反馈环路
研究PAPA综合征(由PSTPIP1显性突变引起的遗传性自身炎症性疾病)的分子发病机制。PAPA相关PSTPIP1突变激活pyrin炎症小体,触发pyrin-IL-18-IFN-γ正反馈环路;在5/5例难治性PAPA患者中,在IL-1抑制基础上加用JAK抑制剂与临床改善相关。
要点
- PAPA相关PSTPIP1突变激活pyrin炎症小体,而非NLRP3、NLRC4或AIM2炎症小体。
- PAPA患者单核细胞经IFN-γ priming后以pyrin依赖方式释放IL-18。
- 5/5例难治性PAPA患者加用JAK抑制剂后临床改善。
核心结论
- PAPA相关PSTPIP1突变触发pyrin-IL-18-IFN-γ正反馈环路,驱动PAPA疾病活动,是JAK抑制的靶点。
研究设计与样本
- 研究采用基因敲除和敲入小鼠构建动物模型,并使用THP1和逆转录病毒转导的U937人髓系白血病细胞系、外周血单个核细胞、小干扰RNA敲低、定点突变、细胞因子免疫测定、免疫共沉淀和免疫印迹研究炎症小体激活。
- 通过免疫组织化学评估皮肤细胞因子水平,并在体外用外周血单个核细胞、在体内对5例治疗难治性PAPA患者评估对Janus激酶(JAK)抑制剂的反应性。
主要发现
- PAPA敲入小鼠模型未能重现人类疾病。
- 在人髓系细胞系模型中,PAPA相关PSTPIP1突变激活pyrin炎症小体,但不激活NLRP3、NLRC4或AIM2炎症小体。
- pyrin炎症小体激活不依赖pyrin丝氨酸去磷酸化的经典途径,并被破坏pyrin-PSTPIP1相互作用的p.W232A PSTPIP1突变阻断。
- PAPA患者单核细胞经IFN-γ priming后以pyrin依赖方式释放IL-18;IFN-γ在PAPA患者炎症真皮中丰富,但在特发性坏疽性脓皮病患者中不丰富。
- 体外JAK抑制剂治疗减弱IFN-γ介导的pyrin诱导和IL-18释放;在5/5例PAPA患者中,在IL-1抑制基础上加用JAK抑制剂治疗与临床改善相关。
临床怎么用
- 在5/5例治疗难治性PAPA患者中,在IL-1抑制基础上加用JAK抑制剂治疗与临床改善相关。
局限性
- PAPA敲入小鼠模型未能重现人类疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study the molecular pathogenesis of PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome, a debilitating hereditary autoinflammatory disease caused by dominant mutation in PSTPIP1. METHODS: Gene knock-out and knock-in mice were generated to develop an animal model. THP1 and retrovirally transduced U937 human myeloid leukaemia cell lines, peripheral blood mononuclear cells, small interfering RNA (siRNA) knock-down, site-directed mutagenesis, cytokine immunoassays, coimmunoprecipitation and immunoblotting were used to study inflammasome activation. Cytokine levels in the skin were evaluated by immunohistochemistry. Responsiveness to Janus kinase (JAK) inhibitors was evaluated ex vivo with peripheral blood mononuclear cells and in vivo in five treatment-refractory PAPA patients. RESULTS: The knock-in mouse model of PAPA did not recapitulate the human disease. In a human myeloid cell line model, PAPA-associated PSTPIP1 mutations activated the pyrin inflammasome, but not the NLRP3, NLRC4 or AIM2 inflammasomes. Pyrin inflammasome activation was independent of the canonical pathway of pyrin serine dephosphorylation and was blocked by the p.W232A PSTPIP1 mutation, which disrupts pyrin-PSTPIP1 interaction. IFN-γ priming of monocytes from PAPA patients led to IL-18 release in a pyrin-dependent manner. IFN-γ was abundant in the inflamed dermis of PAPA patients, but not patients with idiopathic pyoderma gangrenosum. Ex vivo JAK inhibitor treatment attenuated IFN-γ-mediated pyrin induction and IL-18 release. In 5/5 PAPA patients, the addition of JAK inhibitor therapy to IL-1 inhibition was associated with clinical improvement. CONCLUSION: PAPA-associated PSTPIP1 mutations trigger a pyrin-IL-18-IFN-γ positive feedback loop that drives PAPA disease activity and is a target for JAK inhibition.
引用
- Lee W, Stone DL, Hoffmann P, et al. Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne. Ann Rheum Dis. 2024. PMID: 38408849. doi:10.1136/ard-2023-225085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。